FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207721> ?p ?o ?g. }

• W4387207721 endingPage "S6" @default.
• W4387207721 startingPage "S6" @default.
• W4387207721 abstract "To report a final analysis evaluating physician and patient-reported outcomes of early breast cancer patients receiving moderate hypofractionation or ultra-hypofractionated whole breast radiotherapy (RT).Between April 4, 2018, and February 11, 2020, patients with localized breast cancer (T1-T3, N0-N1, and M0) managed with breast-conserving surgery (BCS) were enrolled. Patients were randomized to receive whole breast RT with moderate hypofractionation to 40 Gy in 15 fractions (Arm A) or ultra-hypofractionation to 25 Gy in 5 fractions (Arm B). An optional concurrent integrated boost to 48 Gy on Arm A or 30 Gy on Arm B was allowed. Early toxicity (<3 months), late toxicity (> 3 months), quality of life (QOL), cosmesis, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and deterioration of cosmesis were analyzed.One hundred and seven patients were randomized to moderate hypofractionation (n = 54) or ultra-hypofractionation (n = 53). With a median follow-up of 36 months, no significant differences in patient characteristics were noted between the two arms. There were no patients with a grade ≥3 or higher toxicity. Grade 2 toxicities were 7.4% in Arm A and 7.5% in Arm B, and primarily consisted of radiation dermatitis (6 patients), fibrosis (1 patient) and lymphedema (1 patient). The average Harvard Cosmesis score and overall QoL were similar between arms at all time points, with no patients developing cosmetic deterioration. Patient-reported moderate to severe radiation skin burns were more commonly reported in Arm A (21.05%) vs. Arm B (6.25%) at the end of treatment (EOT) (p = 0.078). At EOT, patients receiving moderate hypofractionation had higher mean toxicity scores in breast tenderness (2.66 vs. 1.5, p = 0.018), skin flaking or peeling (0.63 vs. 0.06, p = 0.035), blistering (0.74 vs. 0.06, p = 0.028), pruritis (2.53 vs. 0.87, p < 0.001), erythema (4.24 vs. 2.0, p <0.001), telangiectasias (1.0 vs. 0.28, p = 0.021). Additionally, patients receiving moderate hypofractionation reported significantly worse changes from baseline at EOT in breast tenderness (-2.25 vs. -.86, p = 0.02), telangiectasia (-0.81 vs. 0.18, p = 0.012), skin discoloration (-4.31 vs. -1.04, p < 0.001), skin flaking or peeling (-.55 vs. 0.04, p = 0.053), blistering (-0.82 vs. -0.07, p = 0.033), and pruritus (-2.27 vs. -.67, p = 0.002). There was a return to baseline in all patient-reported breast domains by 3 months (p >0.05) in both arms.Ultra-hypofractionated whole breast irradiation, consisting of 25 Gy in 5 fractions, provided comparable provider assessed toxicity and cosmetic outcomes to 40 Gy in 15 fractions. At the EOT assessment, ultra-hypofractionation had a better patient reported toxicity profile. Our findings provide further evidence to support daily ultra-hypofractionated whole breast radiotherapy as an appropriate treatment option for early-stage breast cancer." @default.
• W4387207721 created "2023-09-30" @default.
• W4387207721 creator A5006151030 @default.
• W4387207721 creator A5016852500 @default.
• W4387207721 creator A5024662261 @default.
• W4387207721 creator A5030089962 @default.
• W4387207721 creator A5036038074 @default.
• W4387207721 creator A5036770719 @default.
• W4387207721 creator A5039358235 @default.
• W4387207721 creator A5040197178 @default.
• W4387207721 creator A5042478985 @default.
• W4387207721 creator A5043792798 @default.
• W4387207721 creator A5044939667 @default.
• W4387207721 creator A5046778428 @default.
• W4387207721 creator A5075103458 @default.
• W4387207721 creator A5087495484 @default.
• W4387207721 creator A5088829777 @default.
• W4387207721 creator A5090700846 @default.
• W4387207721 date "2023-10-01" @default.
• W4387207721 modified "2023-10-17" @default.
• W4387207721 title "Physician and Patient-Reported Outcomes of a Phase III Trial of Ultra-Hypofractionated vs. Moderate Hypofractionated Radiotherapy to the Whole Breast after Breast-Conserving Surgery" @default.
• W4387207721 doi "https://doi.org/10.1016/j.ijrobp.2023.06.213" @default.
• W4387207721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784534" @default.
• W4387207721 hasPublicationYear "2023" @default.
• W4387207721 type Work @default.
• W4387207721 citedByCount "0" @default.
• W4387207721 crossrefType "journal-article" @default.
• W4387207721 hasAuthorship W4387207721A5006151030 @default.
• W4387207721 hasAuthorship W4387207721A5016852500 @default.
• W4387207721 hasAuthorship W4387207721A5024662261 @default.
• W4387207721 hasAuthorship W4387207721A5030089962 @default.
• W4387207721 hasAuthorship W4387207721A5036038074 @default.
• W4387207721 hasAuthorship W4387207721A5036770719 @default.
• W4387207721 hasAuthorship W4387207721A5039358235 @default.
• W4387207721 hasAuthorship W4387207721A5040197178 @default.
• W4387207721 hasAuthorship W4387207721A5042478985 @default.
• W4387207721 hasAuthorship W4387207721A5043792798 @default.
• W4387207721 hasAuthorship W4387207721A5044939667 @default.
• W4387207721 hasAuthorship W4387207721A5046778428 @default.
• W4387207721 hasAuthorship W4387207721A5075103458 @default.
• W4387207721 hasAuthorship W4387207721A5087495484 @default.
• W4387207721 hasAuthorship W4387207721A5088829777 @default.
• W4387207721 hasAuthorship W4387207721A5090700846 @default.
• W4387207721 hasConcept C121608353 @default.
• W4387207721 hasConcept C126322002 @default.
• W4387207721 hasConcept C141071460 @default.
• W4387207721 hasConcept C159110408 @default.
• W4387207721 hasConcept C168563851 @default.
• W4387207721 hasConcept C197934379 @default.
• W4387207721 hasConcept C2777757722 @default.
• W4387207721 hasConcept C2777793932 @default.
• W4387207721 hasConcept C2779951463 @default.
• W4387207721 hasConcept C2780943399 @default.
• W4387207721 hasConcept C2781392513 @default.
• W4387207721 hasConcept C2781467025 @default.
• W4387207721 hasConcept C509974204 @default.
• W4387207721 hasConcept C530470458 @default.
• W4387207721 hasConcept C71924100 @default.
• W4387207721 hasConceptScore W4387207721C121608353 @default.
• W4387207721 hasConceptScore W4387207721C126322002 @default.
• W4387207721 hasConceptScore W4387207721C141071460 @default.
• W4387207721 hasConceptScore W4387207721C159110408 @default.
• W4387207721 hasConceptScore W4387207721C168563851 @default.
• W4387207721 hasConceptScore W4387207721C197934379 @default.
• W4387207721 hasConceptScore W4387207721C2777757722 @default.
• W4387207721 hasConceptScore W4387207721C2777793932 @default.
• W4387207721 hasConceptScore W4387207721C2779951463 @default.
• W4387207721 hasConceptScore W4387207721C2780943399 @default.
• W4387207721 hasConceptScore W4387207721C2781392513 @default.
• W4387207721 hasConceptScore W4387207721C2781467025 @default.
• W4387207721 hasConceptScore W4387207721C509974204 @default.
• W4387207721 hasConceptScore W4387207721C530470458 @default.
• W4387207721 hasConceptScore W4387207721C71924100 @default.
• W4387207721 hasIssue "2" @default.
• W4387207721 hasLocation W43872077211 @default.
• W4387207721 hasLocation W43872077212 @default.
• W4387207721 hasOpenAccess W4387207721 @default.
• W4387207721 hasPrimaryLocation W43872077211 @default.
• W4387207721 hasRelatedWork W2060905781 @default.
• W4387207721 hasRelatedWork W2126696112 @default.
• W4387207721 hasRelatedWork W2362428144 @default.
• W4387207721 hasRelatedWork W2441734853 @default.
• W4387207721 hasRelatedWork W2905893840 @default.
• W4387207721 hasRelatedWork W3029766897 @default.
• W4387207721 hasRelatedWork W3197193940 @default.
• W4387207721 hasRelatedWork W3210741957 @default.
• W4387207721 hasRelatedWork W4280570548 @default.
• W4387207721 hasRelatedWork W4387207721 @default.
• W4387207721 hasVolume "117" @default.
• W4387207721 isParatext "false" @default.
• W4387207721 isRetracted "false" @default.
• W4387207721 workType "article" @default.